Latest Weight-Loss Drug Faces Shortages from bhopal blood Watch Video

⏲ Duration: 1:30
👁 View: 6.2M times
✓ Published: 19-Apr-2024

Description:
Latest Weight-Loss Drug , Faces Shortages .<br/>The United States Food and Drug Administration <br/>(FDA) says that high demand has left the latest <br/>weight-loss drug, Zepbound, in short supply.<br/>'Newsweek' reports that the Eli Lilly product<br/>is expected to experience limited availability <br/>through Q2 of 2024 as surging demand has <br/>outpaced the manufacturer's expectations.<br/>We have experienced <br/>an unparalleled surge in <br/>demand for our type 2 <br/>diabetes and obesity medicines, Eli Lilly spokesperson, via 'Newsweek'.<br/>We recognize this situation may <br/>cause a disruption in peoples' <br/>treatment regimens and are <br/>working with purpose and <br/>urgency to help meet <br/>the surge in demand, Eli Lilly spokesperson, via 'Newsweek'.<br/>The FDA said that Novo Nordisk's weight-loss <br/>drug, Wegovy, is also experiencing a <br/>widespread supply shortage with no end <br/>in sight for the drug's limited availability.<br/>By the year 2030, 'Newsweek' reports <br/>that the weight-loss drug market is <br/>expected to grow to about $100 billion.<br/>We expect our investments <br/>in manufacturing and supply <br/>capacity to progressively increase <br/>production of our medicines <br/>throughout 2024 and beyond, Eli Lilly spokesperson, via 'Newsweek'.<br/>Over the past year, manufacturer Eli Lilly <br/>has already seen share prices rise over 102%.<br/>The company has announced plans <br/>to expand operations to meet increased <br/>demand for its incretin products which are <br/>used in the firm's diabetes treatments. .<br/>Incretin mimics gut hormones <br/>that regulate blood sugar <br/>while also suppressing appetite